Abbott has announced it has received approval from the US FDA for its Xience Sierra, the newest generation of the company’s gold-standard Xience everolimus-eluting coronary stent system.
A press release reports that Xience stents are among the world’s most-used and studied stents and have an exceptional safety record with low rates of complications. Design and technology advances in this generation of Xience include features specifically designed for the treatment of complex blockages that now account for up to 70% of cases.
Design innovations in XIENCE Sierra include a thinner profile, increased flexibility, longer lengths, and small diameters. The new stent and delivery system were specifically developed for the treatment of complex cases, including people with multiple or totally blocked vessels.
Chuck Brynelsen, senior vice president of Abbott’s vascular business, comments: “We developed Xience Sierra so that physicians can more easily deliver the stent even in challenging cases,” said s. “The updated design and improved deliverability mean doctors can access and unblock difficult-to-treat lesions with more flexibility and precision than other stents.”
Abbott received Regulatory approval for Xience Sierra in Japan in April 2018, and CE mark in Europe in October 2017.
